Yifeng Pharmacy Chain Co., Ltd. (SHA:603939)
22.61
-0.06 (-0.26%)
Sep 16, 2026, 3:00 PM CST
Yifeng Pharmacy Chain Revenue
Yifeng Pharmacy Chain had revenue of 6.04B CNY in the quarter ending June 30, 2026, with 5.82% growth. This brings the company's revenue in the last twelve months to 24.84B, up 3.41% year-over-year. In the year 2025, Yifeng Pharmacy Chain had annual revenue of 24.43B with 1.54% growth.
Revenue (ttm)
24.84B
Revenue Growth
+3.41%
P/S Ratio
1.10
Revenue / Employee
637.73K
Employees
38,953
Market Cap
27.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.43B | 371.01M | 1.54% |
| Dec 31, 2024 | 24.06B | 1.47B | 6.53% |
| Dec 31, 2023 | 22.59B | 2.70B | 13.59% |
| Dec 31, 2022 | 19.89B | 4.56B | 29.75% |
| Dec 31, 2021 | 15.33B | 2.18B | 16.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 27.97B |
| LBX Pharmacy Chain Joint Stock Company | 22.46B |
| Luyan Pharma | 21.43B |
| Cachet Pharmaceutical | 18.10B |
| Yixintang Pharmaceutical Group | 16.89B |
| ShuYu Civilian Pharmacy Corp. | 10.76B |
| Jianzhijia Pharmaceutical Chain Group | 8.65B |
| Anhui Huaren Health Pharmaceutical | 5.81B |
Yifeng Pharmacy Chain News
- 20 days ago - Yifeng Pharmacy Chain Quarterly report: Q2 2026 - Filings
- 4 months ago - Yifeng Pharmacy Chain Annual report: Q4 2025 - Filings
- 4 months ago - Yifeng Pharmacy Chain Quarterly report: Q1 2026 - Filings
- 10 months ago - Yifeng Pharmacy Chain Quarterly report: Q3 2025 - Filings